AGP Executive Report
Last update: 2 hours agoLiechtenstein Royal Drama: A new report digs into a bitter split inside the Princely House of Liechtenstein, with competing versions of the family story and fresh allegations over status, authority, and who gets to define the past. EU Rare-Disease Breakthrough: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment for cerebral adrenoleukodystrophy (cALD) in the EU, with an initial Germany launch expected by year-end. EU Biotech Expansion: Neuren’s Rett syndrome treatment (Daybu/trofinetide) is moving toward first commercial sales across the EU, including Liechtenstein and Norway, after the landmark approval. Onchain Finance: Ondo launched tokenised “Intelligent Portfolios” built on BlackRock strategies, letting investors mint/redeem a single onchain token for diversified exposure. Space Research Pathway: Switzerland and Liechtenstein’s CSA is creating a route for experiments to move from ground testing and parabolic flights to the ISS, with selected opportunities for orbital access. Tech & Mobility Policy: Germany clarified visa rules for foreign IT specialists, while Liechtenstein-linked Schengen travel tech (EES) continues to face rollout delays in multiple countries.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
